Drug Profile
Pemirolast sodium - RSPR Pharma
Alternative Names: CRD 007Latest Information Update: 21 Sep 2020
Price :
$50
*
At a glance
- Originator Cardoz
- Developer Cardoz; Karolinska Institute; Karolinska University Hospital; RSPR Pharma; Sahlgrenska University Hospital; University of Amsterdam
- Class Antiallergics; Antiasthmatics; Nonsteroidal anti-inflammatories; Pyridines; Pyrimidinones; Small molecules
- Mechanism of Action Mast cell stabilisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Asthma
- No development reported Allergic asthma; Vasculitis
Most Recent Events
- 21 Sep 2020 No development reported - Phase-II for Allergic asthma in Sweden (PO)
- 21 Sep 2020 No development reported - Phase-II for Asthma (Adjunctive treatment) in United Kingdom, Poland, Bulgaria, Denmark (PO)
- 28 Apr 2017 Chemical structure information added